Multivariate Cox regression analysis of risk factors after ALL-type primary therapy
| Parameter . | Hazard ratio . | LCL . | UCL . | P . |
|---|---|---|---|---|
| WBC | 1.01 | 1.005 | 1.02 | .0004 |
| iMPO | 0.27 | 0.090 | 0.83 | .022 |
| Parameter . | Hazard ratio . | LCL . | UCL . | P . |
|---|---|---|---|---|
| WBC | 1.01 | 1.005 | 1.02 | .0004 |
| iMPO | 0.27 | 0.090 | 0.83 | .022 |
Results of the multivariate Cox regression analysis of EFS in cases without evidence of a preexisting genetic disease or the specified gene fusions (ETV6/RUNX1, RUNX1/RUNX1T1, PML/RARA, or BCR/ABL1) primarily treated with ALL-type therapy. For the treatment type, 11 factors that withstood the univariate prescreening (listed in “Patients and methods”) were included in the model.
LCL, lower limit of confidence interval; UCL, upper limit of confidence interval.